GammaTile Therapy is a safe and effective, surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors.

- Extends local recurrence-free survival with minimal complications
- Reduces patient burden and helps preserve quality of life
- Facilitates favorable reimbursement (CMS craniotomy code: ICD-10 MS-DRG 23)

AN ELOQUENT SOLUTION

Clinical efficacy, immediacy, and efficiency

- Enables immediate treatment at resection with no additional hospital stay
- Integrates into the surgical workflow for procedural ease and speed
- Approximately 6 minutes to complete GammaTile placement
- Simplifies care with 100% "built-in" compliance and no special interoperative precautions or contraindications with systemic therapies

REFERENCES

GammaTile Therapy is a safe and effective, surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors.

- Extends local recurrence-free survival with minimal complications
- Reduces patient burden and helps preserve quality of life
- Facilitates favorable reimbursement (CMS craniotomy code: ICD-10 MS-DRG 23)

**Clinical efficacy, immediacy, and efficiency**

- Enables immediate treatment at resection with no additional hospital stay
- Integrates into the surgical workflow for procedural ease and speed
- Approximately 6 minutes to complete GammaTile placement
- Simplifies care with 100% "built-in" compliance and no special interventional precautions or contraindications with systemic therapies

**References**

GammaTile | STaRT™

GammaTile Therapy is a surgically targeted radiation therapy (STaRT) that provides immediate, dose-intense treatment at completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy extends local recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.

An eloquent solution

GammaTile Therapy targets cancer cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications. Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment.

- 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
- 88% of the therapeutic dose is delivered within 30 days with more than 95% of the dose delivered by 6 weeks.
- Favorable depth-dose profile optimizes local tumor control.

Bioresorbable, conformable collagen tile preserves healthy tissue

- Provides a structural offset of the radiation source from normal brain tissue
- Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles
- Minimizes local hot and cold spots
- Facilitates rapid, accurate placement to deliver a predictable radiation dose

EXCELLENT SAFETY PROFILE | COMPARABLE TO OR BETTER THAN CURRENTLY AVAILABLE TREATMENTS

- Repeat external beam radiation therapy (EBRT) 1–2
- Traditional brachytherapy 3,4
- GammaTile Therapy 1

Defined as common terminology criteria for adverse events (CTCAE), Grade 1–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.

Colors indicate radiation location and intensity from the 2 types of treatment. Blue-green indicates lower radiation levels. Red indicates higher levels. Area of treatment intent corresponds to the continuous lighter circles.

GammaTile Therapy enhances local control and optimizes efficacy

- 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
- 88% of the therapeutic dose is delivered within 30 days with more than 95% of the dose delivered by 6 weeks.
- Favorable depth-dose profile optimizes local tumor control.
GammaTile Therapy is a surgically targeted radiation therapy (STaRT) that provides immediate, dose-intense treatment at completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy extends local recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.

An eloquent solution
GammaTile Therapy targets cancer cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.

Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment.

GammaTile Therapy enhances local control and optimizes efficacy
• 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
• 88% of the therapeutic dose is delivered within 30 days with more than 95% of the dose delivered by 6 weeks.
• Favorable depth-dose profile optimizes local tumor control.

Bioresorbable, conformable collagen tile preserves healthy tissue
• Provides a structural offset of the radiation source from normal brain tissue
• Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles
• Minimizes local hot and cold spots
• Facilitates rapid, accurate placement to deliver a predictable radiation dose

EXCELLENT SAFETY PROFILE | COMPARABLE TO OR BETTER THAN CURRENTLY AVAILABLE TREATMENTS

<table>
<thead>
<tr>
<th>Treatment Type</th>
<th>Radiation-Related Brain Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeated external beam radiation therapy (EBRT)</td>
<td>0–24%</td>
</tr>
<tr>
<td>Traditional brachytherapy</td>
<td>16–44%</td>
</tr>
<tr>
<td>GammaTile Therapy</td>
<td>12.5%</td>
</tr>
</tbody>
</table>

Defined as common terminology criteria for adverse events (CTCAE), Grade 1–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.

Colors indicate radiation location and intensity from the 2 types of treatment. Blue-green indicates lower radiations levels, red indicates higher levels. Area of treatment intent corresponds to the continuous lighter circles.

† The extracranial dose is likely lower than shown, as the planning system did not utilize inhomogeneity corrections.

Gammatile Therapy enhances local control and optimizes efficacy
• 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
• 88% of the therapeutic dose is delivered within 30 days with more than 95% of the dose delivered by 6 weeks.
• Favorable depth-dose profile optimizes local tumor control.

Bioresorbable, conformable collagen tile preserves healthy tissue
• Provides a structural offset of the radiation source from normal brain tissue
• Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles
• Minimizes local hot and cold spots
• Facilitates rapid, accurate placement to deliver a predictable radiation dose

EXCELLENT SAFETY PROFILE | COMPARABLE TO OR BETTER THAN CURRENTLY AVAILABLE TREATMENTS

<table>
<thead>
<tr>
<th>Treatment Type</th>
<th>Radiation-Related Brain Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeated external beam radiation therapy (EBRT)</td>
<td>0–24%</td>
</tr>
<tr>
<td>Traditional brachytherapy</td>
<td>16–44%</td>
</tr>
<tr>
<td>GammaTile Therapy</td>
<td>12.5%</td>
</tr>
</tbody>
</table>

Defined as common terminology criteria for adverse events (CTCAE), Grade 1–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.

Colors indicate radiation location and intensity from the 2 types of treatment. Blue-green indicates lower radiations levels, red indicates higher levels. Area of treatment intent corresponds to the continuous lighter circles.

† The extracranial dose is likely lower than shown, as the planning system did not utilize inhomogeneity corrections.
GammaTile Therapy is a surgically targeted radiation therapy (STaRT) that provides immediate, dose-intense treatment at completion of resection. By getting a head start on fighting the tumor, resection plus GammaTile Therapy extends local recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.

An eloquent solution
GammaTile Therapy targets cancer cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.

Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment.

GammaTile Therapy enhances local control and optimizes efficacy

- 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
- 88% of the therapeutic dose is delivered within 30 days with more than 95% of the dose delivered by 6 weeks.
- Favorable depth-dose profile optimizes local tumor control.

Bioresorbable, conformable collagen tile preserves healthy tissue
- Provides a structural offset of the radiation source from normal brain tissue
- Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles
- Minimizes local hot and cold spots
- Facilitates rapid, accurate placement to deliver a predictable radiation dose

GammaTile Therapy enhances local control and optimizes efficacy

- 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
- 88% of the therapeutic dose is delivered within 30 days with more than 95% of the dose delivered by 6 weeks.
- Favorable depth-dose profile optimizes local tumor control.

Bioresorbable, conformable collagen tile preserves healthy tissue
- Provides a structural offset of the radiation source from normal brain tissue
- Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles
- Minimizes local hot and cold spots
- Facilitates rapid, accurate placement to deliver a predictable radiation dose

Colors indicate radiation location and intensity from the 2 types of treatment. Blue-green indicates lower radiation levels. Red indicates higher levels. Area of treatment intent corresponds to the continuous lighter circles.

• The extracranial dose is likely lower than shown, as the planning system did not utilize inhomogeneity corrections.

EXCELLENT SAFETY PROFILE | COMPAREABLE TO OR BETTER THAN CURRENTLY AVAILABLE TREATMENTS

<table>
<thead>
<tr>
<th>Treatment Type</th>
<th>Radiation-Related Brain Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeat external beam radiation therapy (EBRT)</td>
<td>0–24%</td>
</tr>
<tr>
<td>Traditional brachytherapy</td>
<td>16–44%</td>
</tr>
<tr>
<td>GammaTile Therapy</td>
<td>12.8%</td>
</tr>
</tbody>
</table>

Defined as common terminology criteria for adverse events (CTCAE). Grade 1–5 possibly or probably related to GammaTile Therapy placement occurring at any time during follow-up.
GammaTile Therapy is a safe and effective, surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors.

- Extends local recurrence-free survival with minimal complications
- Reduces patient burden and helps preserve quality of life
- Facilitates favorable reimbursement (CMS craniotomy code: ICD-10 MS-DRG 23)

**AN ELOQUENT SOLUTION**

<table>
<thead>
<tr>
<th>Immediate Treatment</th>
<th>Precise Dosing</th>
<th>Safe of Use</th>
<th>Reduced Burden</th>
<th>Ensured Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical efficacy, immediacy, and efficiency**

- Enables immediate treatment at resolution with no additional hospital stay
- Integrates into the surgical workflow for procured ease and speed
- Approximately 6 minutes to complete GammaTile placement
- Simplifies care with 100% “built-in” compliance and no special inpatient precautions or contraindications with systemic therapies

**REFERENCES**


Refer to the instructions for use for a complete description of all warnings, precautions, and contraindications.

**PRODUCT ORDERING SPECIFICATIONS**

<table>
<thead>
<tr>
<th>PRODUCT NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>GT-06</td>
<td>GammaTile Therapy Device – 6 Pack</td>
</tr>
<tr>
<td>GT-03</td>
<td>GammaTile Therapy Device – 3 Pack</td>
</tr>
</tbody>
</table>

©2018 GT Medical Technologies, Inc.  |  All rights reserved
GammaTile and STaRT are registered trademarks of GT Medical Technologies, Inc.  |  OCT 2018  |  MKT-001 Rev A

**THE RIGHT TREATMENT AT THE RIGHT TIME**

GammaTile Therapy
An eloquent solution for recurrent brain tumors

Indication for use: GammaTile is intended to deliver radiation therapy in patients with recurrent intracranial neoplasms.

For decades, clinicians have sought better treatment options for patients with brain tumors that would effectively target cancer cells while preserving eloquent tissue. Driven to overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces to address this critical, unmet need. Extensive clinical expertise informed the design of GammaTile Therapy, and deep medical device experience guides the company.